Santana T, et al. - Clinicopathological and follow-up data of 25 cases diagnosed as salivary duct carcinoma (SDC) was obtained in order to examine the prognostic indications of biomarker immunoprofile in a cohort of SDC and to recognize molecular features via next-generation sequencing (NGS). AR, GATA3, and CK5/6 were expressed by most cases and about 42% expressed ER-2/neu. In seven of 15 cases, ERBB2 gene amplification was proven through fluorescence in situ hybridization. Apocrine HER2 (AR+/HER2+) subtype was significantly related to lower overall survival. NGS analysis exhibited nine pathogenic mutations in seven SDC cases, and HRAS was the most often mutated gene followed by PIK3CA and TP53. Homozygous deletion of locus 9p21 (CDKN2A) was exhibited by one case and MDM2 amplification by another. In summary, we showed that in SDC Apocrine HER2 (AR+/HER2+) is a likely biomarker of poor outcomes. Moreover, NGS analysis showed recurrent mutations in SDC.